News

Orasi Medical has opened its new Tokyo office. The new office is expected to allow Orasi Medical to aid Japanese pharmaceutical companies in developing medicines for CNS diseases

Schering-Plough has revealed final results of a Saphris long-term schizophrenia relapse prevention clinical study. In the double-blind phase of the study, time to relapse or impending relapse, the

Celldex Therapeutics (Celldex) has reported the first patient dosing in a phase 1/2 study of its vaccine candidate, CDX-1401, in patients with malignant solid tumors that express NY-ESO-1.

Mpex Pharmaceuticals (Mpex) has reported positive top line results from a phase 2b clinical trial with Aeroquin, a new aerosol formulation of levofloxacin delivered by an optimised Investigational

ARIAD reports result of first interim analysis of phase 3 SUCCEED trial of oral ridaforolimus, an investigational mTOR inhibitor, in metastatic sarcomas. The company said that the phase

CytRx has initiated dose escalation study with its oncology drug candidate tamibarotene combined with TRISENOX injection in patients with relapsed acute promyelocytic leukemia (APL). According to CytRx, there

The Chinese State Food and Drug Administration (SFDA) has approved Abbott’s XIENCE V Everolimus Eluting Coronary Stent System for the treatment of coronary artery disease (CAD) The company

Aastrom Biosciences has reported revenues of $69,000 consisting of product sales for the fourth quarter ended June 30,2009, a decrease when compared to $149,000 for the fourth quarter

Addex Pharmaceuticals’ (Addex) ADX10059 has demonstrated significant potential in a non-human primate model of Parkinson’s disease levodopa induced dyskinesia (PD-LID). ADX10059 is an allosteric inhibitor – a negative